

Portfolio example: Jazz Pharmaceuticals

Vision 2025: USD 5 bn sales, 18 novel product candidates in oncology, neuroscience and cannabinoids

Facts and Figures

Region: North America

Subsector: Specialty Pharma/ Generics

Market capitalization: USD 8.2 bn*


Revenue 2022: USD 3.7 bn



Investment idea

- Blockbuster products for narcolepsy: Xyrem (sodium oxybate), changing guard with successor product Xywav (Xyrem with lower sodium content) - consolidated sales 2022: USD 1.8 bn
- Since 2017: successful build-up of hematology/oncology franchise, including Vyxeos (acute myeloid leukemia AML indication) and Rylaze (acute lymphoblastic leukemia ALL, non-Hodgkin's lymphoma NHL subtypes)
- Acquisition of GW Pharmaceuticals in 2021 for USD 7.2 bn to advance into cannabinoid market (Epidiolex for epilepsy, Sativex for pain)
- Strength of the company lies in strategically sensible, external business development (acquisitions!) and smart life cycle management for existing products

Provider of key products in Percutaneous Transluminal Coronary Angioplasty



ESG valuation of Sustainalytics

ESG Risk Rating

▼ 26.3

Negligible 0-10	Low 10-20	Medium 20-30	High 30-40	Severe 40+
--------------------	--------------	-------------------------	---------------	---------------

UN Global Compact

Compliant	Watchlist	Non-Compliant
------------------	-----------	---------------

Controversy scale

Low: 1	Moderate: 2	Significant: 3	High: 4	Severe: 5
--------	--------------------	----------------	---------	-----------

Controversial business areas

Animal testing

For illustrative purposes only. Holdings and allocations are subject to change. Any reference to a specific company or security does not constitute a recommendation to buy, sell, hold or directly invest in the company or securities.

Source: Jazz Pharmaceuticals, HHS/USDA, Bellevue Asset Management, Bloomberg, Sustainalytics, *as of May 31, 2023